Tetraphase Pharmaceuticals, Inc.
(NASDAQ : TTPH)

( )
TTPH PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
SHPGShire PLC Sponsored ADR
-0.86%171.260.4%$310.10m
AMRNAmarin Corporation Plc Sponsored ADR
-6.00%16.912.0%$244.81m
JAZZJazz Pharmaceuticals Plc
-1.62%141.172.2%$120.91m
PRGOPerrigo Co. Plc
-0.05%59.906.8%$105.90m
GWPHGW Pharmaceuticals PLC Sponsored ADR
1.73%124.846.3%$61.48m
MNKMallinckrodt Plc
-3.62%20.7521.1%$55.15m
ENDPEndo International Plc
-0.26%11.578.9%$50.42m
ICLRICON Plc
-1.64%139.634.1%$44.84m
HZNPHorizon Pharma plc
-2.04%19.657.4%$42.45m
UTHRUnited Therapeutics Corporation
-2.95%109.4414.4%$40.43m
SAGESAGE Therapeutics, Inc.
-0.66%102.009.6%$39.39m
ICPTIntercept Pharmaceuticals, Inc.
-4.26%102.2618.6%$38.77m
CTLTCatalent Inc
-2.68%36.312.4%$37.78m
PTLAPortola Pharmaceuticals, Inc.
0.73%20.687.7%$32.06m
ZGNXZogenix, Inc.
-2.43%42.5510.0%$25.36m

Company Profile

Tetraphase Pharmaceuticals, Inc. engages in the development and production of novel antibiotics for serious and life-threatening bacterial infections. It is currently developing a product candidate, eravacycline, a fully synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Watertown, MA.